Topic:

Partnering

Latest Headlines

Latest Headlines

After burning up $349M, CymaBay aims for Nasdaq as IPOs get shaky

Three years ago, Sanofi walked away from a $375 million diabetes partnership with Metabolex, which had just salved the wound with a new pact with J&J. Now, operating under a new name--CymaBay--and armed with a fresh $38 million raise from late last year, the small biotech is floating plans for a $30 million IPO, looking to cash in on the lingering biotech boom.

GlaxoSmithKline joins a Big Pharma immuno-oncology R&D alliance

GlaxoSmithKline is taking a berth next to teams from AstraZeneca, Pfizer and Johnson & Johnson in an ambitious alliance of industry giants aimed at discovering some new products in the red-hot cancer R&D field.

AstraZeneca expands StarPharma deal for cancer drug delivery tech

AstraZeneca has expanded its deal with Australia's StarPharma, originally inked in September 2012, to use its drug delivery technology with a cancer drug in AstraZeneca's pipeline.

Daiichi Sankyo, UCSF strike deal to combat neurodegeneration

The University of California, San Francisco, is teaming up with Japanese drugmaker Daiichi Sankyo for a drug-discovery pact focused on tackling neurodegenerative diseases.

Merck KGaA signs on to sell Auxogyn's IVF test

Germany's Merck KGaA signed a licensing agreement with Menlo Park, CA-based Auxogyn to sell its fertility-enhancing diagnostic test in Europe and Canada with an option to extend the agreement to other countries.

Lilly, Pfizer partner with Lieber Institute on brain research

The Lieber Institute for Brain Development is partnering with Astellas, Eli Lilly, Lundbeck, Pfizer and Roche to launch an early-stage research consortium to study the genetic mechanisms at work in brain disorders.

Evotec lands two more deals to share risks and rewards of R&D

Germany's Evotec subverts the traditional CRO model by cozying up to its development partners with risk-splitting deals, and the company's approach to R&D has attracted Debiopharm and Convergence Pharmaceuticals with programs in cancer and chronic pain.

CyVek immunoassay technology gets $10M investment

CyVec and its immunoassay technology got a $10 million investment shot in the arm from Minneapolis-based Bio-Techne with an additional promise to acquire the company in the future if certain conditions are met.

Roche's pRED jumps into epigenetics with $521M-plus cancer drug deal

John Reed's Basel-based pRED group at Roche has struck its first epigenetics deal, snapping up rights to Barcelona-based Oryzon's orphan cancer blocker ORY-1001, now being studied in the clinic for acute myeloid leukemia.

Roche's Ventana pairs with Genmab on yet another companion Dx deal

Roche's Ventana Medical Systems will work with Denmark's Genmab to come up with a companion diagnostic test to be paired with a targeted anticancer drug now in development.